Aurobindo Pharma share price gained 19 percent in the early trade on February 19 after the company received an establishment inspection report (EIR) from the US drug regulator.
The company has received EIR with voluntary action initiated (VAI) status from the United States Food and Drug Administration (US FDA).
USFDA inspected Unit IV, a general injectable formulation manufacturing facility at Pashamylaram in Hyderabad, from November 4 to 13, 2019.
At the end of the inspection, USFDA issued a 'Form 483' with 14 observations.
At 0921 hours, Aurobindo Pharma was quoting at Rs 568.15, up Rs 67.95, or 13.58 percent, on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
